310 320
Table 1 – Pretreatment demographic and clinical characteristics by race/ethnicity
White
AA
Hispanic
Combined
p
value
(
n
= 1835)
(
n
= 324)
(
n
= 179)
Age at diagnosis (yr)
64 (59–70)
63 (55–67)
63 (57–69)
64 (58–69)
<
0.001
Body mass index (kg/m
2
)
27 (25–30)
28 (25–31)
28 (26–31)
0.05
Education
<
0.001
High school or less
5% (96)
18% (55)
47% (83)
10% (234)
High school graduate
19% (333)
28% (86)
25% (45)
20% (464)
Some college
23% (411)
23% (70)
16% (29)
22% (510)
College graduate
25% (445)
17% (51)
7% (13)
22% (509)
Graduate/professional
28% (510)
14% (43)
4% (7)
25% (560)
Marital status
<
0.001
Not married
16% (292)
36% (108)
23% (40)
19% (440)
Married
84% (1498)
64% (196)
77% (136)
81% (1830)
Insurance
<
0.001
Medicaid/None
1% (23)
10% (31)
7% (12)
3% (66)
VA/military/other
1% (27)
3% (11)
6% (11)
2% (49)
Medicare
47% (864)
44% (143)
37% (66)
46% (1073)
Private/HMO
50% (921)
43% (139)
50% (90)
49% (1150)
Employment
<
0.001
Full time
45% (819)
35% (111)
36% (64)
43% (994)
Part time
8% (153)
7% (21)
5% (9)
8% (183)
Retired
44% (797)
48% (153)
43% (77)
44% (1027)
Unemployed
3% (50)
10% (32)
16% (28)
5% (110)
Annual income
<
0.001
$30 000
13% (215)
40% (116)
56% (92)
20% (423)
$30 001–$50 000
19% (328)
23% (65)
18% (29)
20% (422)
$50 001–$100 000
34% (573)
25% (71)
18% (29)
31% (627)
$100 001
34% (578)
12% (36)
8% (13)
29% (627)
TIBI
<
0.001
0–2
27% (483)
26% (81)
46% (81)
28% (645)
3–5
57% (1024)
53% (162)
44% (78)
55% (1264)
6–8
13% (236)
17% (53)
10% (17)
13% (306)
9–15
3% (54)
4% (12)
1% (2)
3% (68)
D’Amico risk group
<
0.001
Low
46% (837)
41% (132)
47% (83)
45% (1052)
Intermediate
39% (722)
38% (124)
37% (65)
39% (911)
High
15% (272)
21% (67)
17% (30)
16% (369)
Clinical T stage
<
0.001
T1
75% (1371)
80% (257)
82% (147)
76% (1775)
T2
25% (457)
20% (66)
18% (32)
24% (555)
Biopsy Gleason score
<
0.001
6
52% (957)
50% (160)
54% (96)
52% (1213)
3 + 4
28% (521)
31% (100)
21% (37)
28% (658)
4 + 3
10% (187)
11% (34)
12% (22)
10% (243)
8
9% (165)
9% (29)
13% (23)
9% (217)
Prostate-specific antigen
<
0.001
<
4 ng/ml
22% (402)
19% (62)
16% (28)
21% (492)
4–9.9 ng/ml
67% (1222)
60% (196)
70% (126)
66% (1544)
10–19.9 ng/ml
9% (163)
14% (45)
11% (19)
10% (227)
20–50 ng/ml
3% (48)
6% (21)
3% (6)
3% (75)
Any hormone therapy in first year
<
0.001
No
88% (1619)
81% (264)
82% (146)
87% (2029)
Yes
12% (216)
19% (60)
18% (33)
13% (309)
Surgery type
<
0.001
Open
20% (203)
31% (42)
24% (23)
22% (268)
Robot-assisted
78% (794)
67% (90)
74% (70)
77% (954)
Other
2% (19)
2% (3)
2% (2)
2% (24)
Nerve-sparing procedure
<
0.001
Yes
93% (767)
81% (91)
91% (74)
91% (932)
No
7% (59)
19% (21)
9% (7)
9% (87)
IMRT
<
0.001
No
78% (1369)
68% (191)
82% (131)
77% (1691)
Yes
22% (385)
32% (90)
18% (28)
23% (503)
Data are presented as median (interquartile range) for continuous variables.
AA = African-American; VA = Veterans Association; HMO = Health Maintenance Organization; IMRT = intensity-modulated radiation therapy.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 0 7 – 3 1 4
310